UCB BIOPHARMA SPRL
Created in 1928, by the merger of 13 factories manufacturing various intermediate chemicals, UCB has transformed itself over recent decades from a hybrid pharmaceuticals and chemicals Company into a biopharmaceutical Company through the divestiture of its surface specialties and film businesses. In addition, in 2004, the Celltech acquisition (leading British biotech Company) added a large-molecule, biological business to complement UCB’s existing small molecule pharmaceutical portfolio. In 2006, UCB acquired Schwarz Pharma, strengthening its resources, pipeline and product portfolio in neurology and taking the Company into new fields such as Parkinson’s disease, restless legs syndrome and fibromyalgia.
UCB is a leading global and research-driven biopharmaceutical Company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products. UCB is a patient-centric Company focusing on Central Nervous System (CNS) diseases and immunological disorders. UCB integrates expertise in large, antibody-based molecules and small, chemically-derived molecules. UCB strategy aims at delivering innovative small and large molecule solutions to specialists for severe diseases in its chosen therapeutic areas. Already the leader in epilepsy, UCB is committed to providing novel solutions for people with severe conditions such as Parkinson’s disease, rheumatoid arthritis, and restless legs syndrome.
Employing more than 7,700 people in over 40 countries, UCB produced revenues of € 4 .2 billion in 2016. The mother Company (UCB SA) and headquarters are located in Belgium Brussels, serving as coordination and governance body for the R&D, production and sales activities of UCB SA and all its affiliates worldwide.
UCB networks with leading global academic and industrial partners ensure access to novel technologies, targets and collaborative services.
Role within BIOMAP
UCB will co-lead WPs 1, 2 and 6 providing strategic and technical industry-related expertise relevant to the activities of the respective work packages. UCB will also contribute to WPs 3 and 5. Specifically, in WP1, UCB will provide clinical development expertise on refining the clinical phenotypes and patients subtypes that develop comorbidities as well as defining relevant, patient-centred clinical outcomes (and instruments) relating to disease, progression, co-morbidities and response to therapy. For WP2, UCB will provide scientific and technical expertise to the development of the computational and data management platforms. UCB will also contribute extensive experience in Artificial Intelligence and Machine Learning to the bio-modelling components of this BIOMAP objective. In WP3, UCB will contribute scientific and technical expertise in the fields of data science w.r.t. the development and validation of a molecular disease taxonomy based on experiences gathered in past IMI projects (e.g. AETIONOMY, PRECISEADS). Furthermore, UCB will support the development of epigenomics/transcriptomics signatures in AD and PSO via UCB’s strong internal translational bioinformatics expertise. If feasible, in WP5 UCB will generate new reagents for exploring patient samples (donated in-kind to the consortia, across the 5 years); identify aberrant signalling profiles from immune cells in peripheral blood of patients via CyToF; phenotype peripheral blood cells to identify novel circulating immune populations and cytokine profiles using skin specific stimuli. As co-lead of WP6, UCB will contribute scientific expertise in the systematic literature review for biomarkers in PsO and AD as well as in the characterization and assessment of novel biomarkers and the development of potential prototype assays to support the diagnosis of AD and PSO.
The UCB team includes:
- Dr. ‘Matladi N. Ndlovu, Global Lead Innovative Precision Medicine Partnerships
- Dr. Owen Davies, Global PsA Medical Affairs and Marketing Strategy Lead (Cimzia, BKZ)
- Dr. Daniela Dastros-Pitei, Head Immunology Clinical Development Practice
- Dr. Phil Scordis, Director, Strategy and Outreach, Data and Translational Sciences
- Prof. Dr. Holger Fröhlich, Director, Data Science Enablement, Data and Translational Sciences
- Dr. Adnan Khan, Principal Scientist, Immunology Research, Immune Bone Therapeutic Area